Autogene cevumeran goes on hold in adjuvant bladder cancer.
ApexOnco Front Page
Recent articles
The deal for ISB 2001 is worth $700m up front.
But could toxicity be holding back filing plans?
Syndax scored the first menin approval, but Kura is first with a licensing deal.
A CD22-directed Car that has had several owners will next year deliver its most important dataset.
GEN1286/PRO1286 features among the latest industry projects to enter clinical trials.
The group touts a 72% ORR with SCIB1, but full Scope data have been pushed back into 2025.
A 5% response rate with IMA402 monotherapy seems unlikely to turn heads.
